Literature DB >> 1080062

Studies of the human factor VIII/von Willebrand's factor protein. II. Identification and characterization of the von Willebrand protein.

H R Gralnick, B S Coller.   

Abstract

The purified factor VIII-related protein we have previously characterized from normal cryoprecipitate possesses both procoagulant activity and vWf activity. We have attempted to isolate and characterize this protein from three patients with severe vWd. This protein is absent or markedly diminished in amount in these vWd patients, as judged by gel filtration, polyacrylamide-gel electrophoresis, and immunoprecipitation assays. Likewise, the procoagulant and vWf activities are deficient. As vWf activity is one of the major biologic functions of either the normal or hemophilic factor VIII-related protein, the purified protein should be designated the f VIII/vWf protein.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1080062

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  5 in total

1.  Factor VIII/von Willebrand factor protein. Galactose a cryptic determinant of von Willebrand factor activity.

Authors:  H R Gralnick
Journal:  J Clin Invest       Date:  1978-08       Impact factor: 14.808

2.  Studies on the mechanism of ristocetin-induced platelet agglutination. Effects of structural modification of ristocetin and vancomycin.

Authors:  B S Coller; H R Gralnick
Journal:  J Clin Invest       Date:  1977-08       Impact factor: 14.808

3.  [A variant of the von Willebrand-Jürgens-syndrome with abnormalities of the factor VIII/von Willebrand factor protein (author's transl)].

Authors:  K Hasler; D Böttcher; R Engelhardt
Journal:  Blut       Date:  1979-01-22

4.  The platelet: life on the razor's edge between hemorrhage and thrombosis.

Authors:  Barry S Coller
Journal:  Transfusion       Date:  2014-08-05       Impact factor: 3.157

5.  Effect of dextran on factor VIII (antihemophilic factor) and platelet function.

Authors:  M Aberg; U Hedner; S E Bergentz
Journal:  Ann Surg       Date:  1979-02       Impact factor: 12.969

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.